Drug Discovery

The Vanderbilt Institute of Chemical Biology held its annual Student Research Symposium on Aug. 1, drawing a record number of registrants and poster presenters. Organized by the Chemical Biology Association of Students, the event showcased cutting-edge research, interdisciplinary collaborations, and exceptional contributions from both trainees and faculty. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

In this episode of Quantum Potential, Craig Lindsley, William K. Warren, Jr. Professor of Medicine, University Distinguished Professor of Biochemistry, Chemistry and Pharmacology and executive director of the Warren Center for Neuroscience Drug Discovery, joins Provost C. Cybele Raver to discuss transformative research exploring how subtle tweaks to brain chemistry could change the way we treat neurodegenerative diseases and chronic pain. Lindsley shares how academic-industry collaborations drive innovation in drug discovery and highlights how Vanderbilt’s scientific workflow is enabling the broader research community to build on its breakthroughs. Read More

Corey Hayford, PhD’21, sat down with us to discuss his experience studying basic science at Vanderbilt and how it played a role in his career. Hayford is now a principal data engineer at Cellarity. Read More

Ashley Brady, PhD’03, assistant dean of biomedical career engagement and strategic partnerships in the BRET Office of Career Development ASPIRE Program and associate professor of medical education and administration, sat down with us to discuss her experience studying basic science at Vanderbilt and how it played a role in her career. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

Lori Rudolph-Owen, an accomplished figure in the biotechnology industry and a Vanderbilt University School of Medicine Basic Sciences alum, shared her insights on career progression and drug development on Oct. 3 as part of BRET’s Ph.D. Career Stories, a series focused on various alums and their professions. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

The Center for Structural Biology in the School of Medicine Basic Sciences will be a hub of research innovation using Carterra’s platform in traditional and AI-driven workflows for characterizing both antibodies and other biomolecules Read More

Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read More